Literature DB >> 14703880

Burden of illness of Crohn's disease in Spain.

J Juan1, R Estiarte, E Colomé, M Artés, F J Jiménez, J Alonso.   

Abstract

OBJECTIVE: To evaluate the burden of Crohn's disease in Spain.
DESIGN: Observational, cross-sectional study of patients affected with Crohn's disease who were attended to in hospitals in Spain.
METHODS: Three structured questionnaires were used: one completed by the gastroenterologists to obtain demographic, clinical and disease activity data; a phone interview to obtain epidemiological and drug utilisation data; and the Spanish version of the Short-Form Health Survey (SF-36).
RESULTS: The annual cost per patient was estimated at Euro 6808-Euro 2104 from direct medical costs and Euro 4704 from indirect costs. Approximate effect sizes for health-related quality of life were as follows: 0.8 for general health, social function, role functioning--physical and vitality; 0.5 for role functioning--emotional, body pain and mental health; and 0.2 for physical function.
CONCLUSION: Crohn's disease causes a significant decrease in health-related quality of life for patients and a considerable economic cost to society, mainly due to hospitalisations and loss of productivity. This burden indicates the importance of health programmes and interventions in reducing the heavy impact of the disease on both patients and society.

Entities:  

Mesh:

Year:  2003        PMID: 14703880     DOI: 10.1016/j.dld.2003.07.002

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  23 in total

1.  Health care costs of complex perianal fistula in Crohn's disease.

Authors:  M Chaparro; C Zanotti; P Burgueño; I Vera; F Bermejo; I Marín-Jiménez; C Yela; P López; M D Martín; C Taxonera; B Botella; R Pajares; A Ponferrada; M Calvo; A Algaba; L Pérez; B Casis; J Maté; J Orofino; N Lara; M García-Losa; X Badia; J P Gisbert
Journal:  Dig Dis Sci       Date:  2013-09-13       Impact factor: 3.199

Review 2.  Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease.

Authors:  Antonio Di Sabatino; Lucio Liberato; Monia Marchetti; Paolo Biancheri; Gino R Corazza
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

3.  Robotic single-site endometriosis resection using near-infrared fluorescence imaging with indocyanine green: a prospective case series and review of literature.

Authors:  Jayapriya Jayakumaran; Zoran Pavlovic; Daniele Fuhrich; Karen Wiercinski; Cynthia Buffington; Aileen Caceres
Journal:  J Robot Surg       Date:  2019-04-01

4.  Cost-of-illness of inflammatory bowel disease patients treated with anti-tumour necrosis factor: A French large single-centre experience.

Authors:  Jean Lawton; Hamza Achit; Lieven Pouillon; Emmanuelle Boschetti; Béatrice Demore; Thierry Matton; Charlène Tournier; Martin Prodel; Laurent Peyrin-Biroulet; Francis Guillemin
Journal:  United European Gastroenterol J       Date:  2019-05-20       Impact factor: 4.623

Review 5.  The economic and quality-of-life burden of Crohn's disease in Europe and the United States, 2000 to 2013: a systematic review.

Authors:  David N Floyd; Sue Langham; Hélène Chevrou Séverac; Barrett G Levesque
Journal:  Dig Dis Sci       Date:  2014-09-26       Impact factor: 3.199

6.  Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease.

Authors:  Monia Marchetti; Nicola L Liberato; Antonio Di Sabatino; Gino R Corazza
Journal:  Eur J Health Econ       Date:  2012-09-14

Review 7.  Crohn's disease: a review of current treatment with a focus on biologics.

Authors:  Julián Panés; Fernando Gomollón; Carlos Taxonera; Joaquin Hinojosa; Juan Clofent; Pilar Nos
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 8.  How expensive is inflammatory bowel disease? A critical analysis.

Authors:  Selwyn Odes
Journal:  World J Gastroenterol       Date:  2008-11-21       Impact factor: 5.742

Review 9.  Efficacy and safety of adalimumab for the Crohn's disease: a systematic review and meta-analysis of published randomized placebo-controlled trials.

Authors:  Yun-Na Song; Ping Zheng; Jun-Hua Xiao; Zhan-Jun Lu
Journal:  Eur J Clin Pharmacol       Date:  2014-06-01       Impact factor: 2.953

10.  Effect of Originator Infliximab Treatment on Disease-Related Hospitalizations, Work Productivity and Activity Impairment, and Health Resource Utilization in Patients with Crohn's Disease in a Real-Life Setting: Results of a Prospective Multicenter Study in Germany.

Authors:  Niels Teich; Michael Bläker; Frank Holtkamp-Endemann; Eric Jörgensen; Andreas Stallmach; Susanne Hohenberger
Journal:  Inflamm Intest Dis       Date:  2020-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.